Publications by authors named "S Kılıckap"
Significant response to [Ac]Ac-DOTATATE therapy in a patient with small cell lung cancer.
Eur J Nucl Med Mol Imaging
January 2025
Background: Although higher-generation TKIs are associated with improved progression-free survival in advanced NSCLC patients with EGFR mutations, the optimal selection of TKI treatment remains uncertain. To address this gap, we developed a web application powered by a reinforcement learning (RL) algorithm to assist in guiding initial TKI treatment decisions.
Methods: Clinical and mutational data from advanced NSCLC patients were retrospectively collected from 14 medical centers.
BACKGROUND This retrospective study from a single center included 289 patients diagnosed with advanced non-small cell lung cancer (NSCLC) between 2010 to 2017 and aimed to evaluate the effects of body mass index (BMI) on overall survival. MATERIAL AND METHODS This retrospective study involved 289 patients diagnosed with metastatic-stage NSCLC at a single institution between January 2010 and December 2017. Patients were categorized into 2 groups based on their BMI at diagnosis: those with a BMI <25 kg/m² and those with a BMI ≥25 kg/m².
View Article and Find Full Text PDFArticle Synopsis
- The study examined the impact of immunotherapy in renal patients with urothelial carcinoma, categorizing them based on their glomerular filtration rate (GFR).
- Results showed that patients with normal GFR had a higher overall response rate and longer duration of response compared to those with low and very low GFRs.
- The findings indicated that while normal GFR patients had better outcomes, immunotherapy still proved effective for patients with impaired renal function who lacked other treatment options.
Article Synopsis
- The study investigates the response to first-line PD-1 inhibitors, pembrolizumab and cemiplimab, in patients with metastatic NSCLC, focusing on those with different PD-L1 tumor proportion scores (TPS).
- It compares survival rates between patients with a PD-L1 TPS of 90% or higher and those with a score of 50% to 89%, finding significantly better outcomes for the higher TPS group in both treatment cohorts.
- Genomic profiling identified specific mutations more prevalent in lower PD-L1 expression tumors, highlighting key biological differences that may influence treatment responses.